Arax Advisory Partners’s First Tracks Biotherapeutics TRAX Stock Holding History
Bought
Maintained
Sold
Other funds holding TRAX
Arax Advisory Partners's TRAX Position: Q3 2026 in Review
Arax Advisory Partners increased its First Tracks Biotherapeutics (TRAX) stake by 70% in Q3 2026, buying an estimated $11.4K and bringing the position to 707 shares worth $25.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3855.
Arax Advisory Partners first reported a position in TRAX in Q2 2026 and has held it in 2 quarters since. 161 funds tracked by Wall St. Rank hold TRAX as of Q3 2026.
- Arax Advisory Partners held 707 shares of First Tracks Biotherapeutics worth $25.1K as of Q3 2026.
- Arax Advisory Partners bought 292 First Tracks Biotherapeutics shares in Q3 2026, an estimated $11.4K.
- First Tracks Biotherapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #3855 holding.
- Arax Advisory Partners first reported a position in First Tracks Biotherapeutics in Q2 2026 and has held it in 2 quarters since.
- 161 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q3 2026.
Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.